In addition, it has been recently demonstrated that the response of myeloma cells to bortezomib could be due to the noncanonical functions of HO-1 which translocates to the nucleus where it plays a role in genetic instability, favoring cancer progression independently of its enzymatic activity [65]. The gene discussed is HMOX1; the disease is cancer.